Immune reactivity in the Moloney strain of murine sarcoma virus oncogenesis: requirement of thymus-derived lymphocytes for in vivo protection
- PMID: 176399
- DOI: 10.1093/jnci/56.3.603
Immune reactivity in the Moloney strain of murine sarcoma virus oncogenesis: requirement of thymus-derived lymphocytes for in vivo protection
Abstract
To study the function of different lymphocyte populations in the Moloney strain of murine sarcoma virus (M-MuSV) tumorigenesis, we gave M-MuSV injections to CBA mice selectively deprived of thymus (T) lymphocytes by thymectomy, X-rradiation, and syngeneic bone marrow injection. Although no tumors appeared in the control group, 80% of the derived mice had tumors that grew progressively and ultimately killed them. In deprived mice, grafted with a syngeneic thymus (reconstituted mice) before or after an M-MuSV injection, tumors regressed or did not develop. Histologically, the lymph nodes and spleens of reconstituted mice, compared to those of deprived animals, showed repopulation of the thymus-dependent areas and prominent follicles in the cortex. Moreover, tumor tissue of reconstituted mice was extensively infiltrated by lymphocytes. To evaluate the number of lymphoid cells needed to prevent or regress M-MuSV tumors, we injected varying amounts of lymphoid cells into deprived mice. Even low lymphocyte numbers (10(6) cells) were sufficient to exert, in some cases, protection against M-MuSV tumorigenesis. This effect was not abolished by subsequent splenectomy or antilymphocyte serum treatment. Finally, deprived mice, given repeated injections of antiserum (hyperimmune) against M-MuSV, had tumors which appeared only after a prolonged latency. From these results, it is concluded that T-cell population integrity is important in affording total host protection against the M-MuSV tumors.
Similar articles
-
Functional activity in vivo of effector T cell populations. III. Protection against Moloney murine sarcoma virus (M-MSV)-induced tumors in T cell deficient mice by the adoptive transfer of a M-MSV-specific cytolytic T lymphocyte clone.Eur J Immunol. 1987 Feb;17(2):173-8. doi: 10.1002/eji.1830170204. Eur J Immunol. 1987. PMID: 3030766
-
Lack of M-MuSV tumour regression associated with T lymphocyte tolerance.Nature. 1980 Jun 26;285(5767):667-8. doi: 10.1038/285667a0. Nature. 1980. PMID: 6248790 No abstract available.
-
Evidence of suppressor cell activity in spleens of mice bearing primary tumors induced by Moloney sarcoma virus.J Exp Med. 1974 Jun 1;139(6):1473-87. doi: 10.1084/jem.139.6.1473. J Exp Med. 1974. PMID: 4598016 Free PMC article.
-
Effects of irradiation, anti-thymocyte serum and corticosteroids on PHA and LPS responsive cells of the mouse.Int Arch Allergy Appl Immunol. 1977;53(6):505-14. doi: 10.1159/000231792. Int Arch Allergy Appl Immunol. 1977. PMID: 324922 Review.
-
Suppressor cells: permitters and promoters of malignancy?Adv Cancer Res. 1979;29:45-125. doi: 10.1016/s0065-230x(08)60846-5. Adv Cancer Res. 1979. PMID: 382778 Review. No abstract available.
Cited by
-
Characterization of gP85gag as an antigen recognized by Moloney leukemia virus-specific cytolytic T cell clones that function in vivo.J Exp Med. 1985 Jul 1;162(1):128-44. doi: 10.1084/jem.162.1.128. J Exp Med. 1985. PMID: 3891902 Free PMC article. Review.
-
Growth pattern of tumours in mice induced by murine Moloney sarcoma-virus and sarcoma-virus-transformed cells.Br J Cancer. 1979 Dec;40(6):932-42. doi: 10.1038/bjc.1979.288. Br J Cancer. 1979. PMID: 230854 Free PMC article.
-
Nonproducer malignant tumor cells with rescuable sarcoma virus genome isolated from a recurrent Moloney sarcoma.J Exp Med. 1978 Aug 1;148(2):408-23. doi: 10.1084/jem.148.2.408. J Exp Med. 1978. PMID: 151722 Free PMC article.
-
Adoptive T cell immunotherapy of MSV-induced tumours in nude mice. Part I. Biology of tumour regression and recurrence.Clin Exp Metastasis. 1983 Jul-Sep;1(3):261-73. doi: 10.1007/BF00736409. Clin Exp Metastasis. 1983. PMID: 6100803
-
Dissecting the immune response to moloney murine sarcoma/leukemia virus-induced tumors by means of a DNA vaccination approach.J Virol. 1999 Mar;73(3):2280-7. doi: 10.1128/JVI.73.3.2280-2287.1999. J Virol. 1999. PMID: 9971811 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources